For how we live.
A single-centre study used continuous glucose monitoring to fine-tune insulin in people fed intravenously overnight. Time-in-range and weight improved — but with 12 patients and no control group, it is proof of concept.
The FDA logged the recall of 8,939 StatStrip Glucose and B-Ketone meters on 23 September, after a software flaw let a scanned barcode linger and file a reading to the wrong patient. It is the agency's most serious tier.
Two 2026 Class I recalls cover Omnipod 5 insulin pods whose soft cannula can be damaged in manufacturing, letting insulin leak instead of reaching the user. The FDA ties under-delivery to a risk of DKA.
A regional Global Burden of Disease analysis attributes 15.8 million healthy life-years lost in 2023 to high body-mass index, and warns of a 346.3% rise in obesity among the young.
The Global Burden of Disease 2023 study estimates 2.33 billion NCD incident cases and 263 million DALYs across Africa, with high blood pressure the single largest driver of the continent's NCD deaths.
Danger lies at both ends. Below 70 mg/dL blood sugar is too low; sustained highs can tip into ketoacidosis above 200 mg/dL or a hyperosmolar crisis above 600. Both extremes are medical emergencies.
There is no single number. Normal depends on which test is used and whether you have fasted — and the cut-offs that define prediabetes and diabetes are lines drawn on a continuous scale.
Since 2024 the FDA has cleared over-the-counter CGMs for people who don't use insulin. The first independent accuracy check in adults without diabetes finds the sensors track the trend but miss the exact number.
A pooled analysis of 315,403 adults finds wealth inequalities in hypertension, diabetes and cholesterol care grow across the care cascade — but the biggest treatment gaps are not where most heart risk could be averted.
Rings and watches sold online promise needle-free glucose readings. The FDA says do not use any of them, and even research-grade non-invasive sensors miss the mark by about a fifth.
An autonomous AI for diabetic retinopathy hit 87.2% sensitivity in primary care. A smartphone acuity test agreed with a reference chart to within 0.07 logMAR. Both are triage, not diagnosis.
Systems that give a diagnosis with no clinician in the loop post high sensitivity in trials. In real-world use, one in six images was too poor to grade — and the strongest numbers come from company-run studies.
A WHO data-set analysis shows how mobile and hospital teams split the load of hypertension, diabetes and epilepsy care during the war, while a separate study tracked dialysis capacity falling.
Algorithms that read short voice recordings can pick up acoustic signs of some conditions. In the largest and most careful studies the signals are real but narrow, sex-specific, and often fail to generalise.
Kidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
National surveys show risk behaviours climbing among adults with diabetes since 2007, while a separate study finds noncommunicable-disease mortality nearly twice as high in the worst-affected province as in the best.
High urate levels track with worsening kidney disease, so treating them seemed a logical way to slow it. Two trials that lowered urate with allopurinol found the kidneys declined at the same rate anyway.
The equation converting A1c to average glucose was built from 507 people. In carriers of sickle cell trait the reading runs about 0.3 percentage points low for the same measured glucose.
A review pooling prevalence across the region ties the projection to modifiable risks that are unusually common there — smoking, inactivity, diabetes — layered on rapid ageing.
New GBD analysis across 21 countries finds one group whose burden fell — children — while incidence rose 92% overall and the sex pattern inverted.
Medicare's cap is statutory; the commercial version is a voluntary manufacturer promise with conditions. Before the caps, 1.3 million adults rationed insulin because of cost.
The first large-scale policy evaluation of medically tailored meals covers 1,866 recipients across 11 health systems. It is quasi-experimental, not randomised — and that is the finding's main limit.
Pooling a decade of research on women with hypertension, diabetes and obesity, researchers found modest blood pressure and metabolic shifts only in select high-risk subgroups.
A Qatar Biobank analysis derived local cut-points and found WHO's standard numbers misclassified more than half of men and nearly half of women in the sample.
A January study forecasts particulate pollution across six Gulf states and reports Qatar highest at 87.90 µg/m³. The modelling is careful; the input data is annual, national and thirty-one points long.
The FDA's revised general wellness policy lets non-invasive devices infer blood pressure, glucose and other physiologic parameters. The regulated line is no longer the measurement — it is the sentence next to it.
Twelve years of English primary care records put a price on weather. The heat effect is loud and short; the cold effect is quiet, cumulative, and much larger.
PpgAge predicts chronological age from consumer wearable photoplethysmography and tracks disease. The same optical method has documented accuracy problems across skin tones.
Age-standardised disability-adjusted life-years fell 12.6% since 2010, but the raw total rose 6.1% to 2.80 billion. Anxiety, depression and diabetes rose fastest even after adjusting for ageing.